NNNN

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +2.36
Percentage change 6.38	%

Scroll to Statements

Index	-	P/E	649.34	EPS (ttm)	0.06	Insider Own	9.57%	Shs Outstand	42.29M	Perf Week	26.08%
Market Cap	5.66B	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	39.69M	Perf Month	367.90%
Enterprise Value	5.65B	PEG	-	EPS next Q	-	Inst Own	0.15%	Short Float	0.11%	Perf Quarter	441.27%
Income	2.56M	P/S	639.79	EPS this Y	-	Inst Trans	310.54%	Short Ratio	0.50	Perf Half Y	-
Sales	8.85M	P/B	93.48	EPS next Y	-	ROA	13.83%	Short Interest	0.04M	Perf YTD	581.98%
Book/sh	0.42	P/C	464.87	EPS next 5Y	-	ROE	15.00%	52W High	38.50 2.21%	Perf Year	-
Cash/sh	0.08	P/FCF	2516.50	EPS past 3/5Y	-50.61% -	ROIC	14.40%	52W Low	5.18 659.65%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	2627.88	Sales past 3/5Y	-40.18% -	Gross Margin	71.91%	Volatility	11.63% 17.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	638.41	EPS Y/Y TTM	5.21%	Oper. Margin	24.34%	ATR (14)	3.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.71	Sales Y/Y TTM	21.97%	Profit Margin	28.95%	RSI (14)	91.23	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	10.71	EPS Q/Q	-267.38%	SMA20	90.26%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-36.00%	SMA50	212.47%	Rel Volume	1.68	Prev Close	36.99
Employees	27	LT Debt/Eq	0.00	Earnings	-	SMA200	299.76%	Avg Volume	87.28K	Price	39.35
IPO	Feb 19, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	146,683	Change	6.38%

Jul-04-25 06:00AM	The IPO market in 2025 is being driven by a clear theme bigger is better (Yahoo Finance)
May-15-25 01:05AM	Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions (GlobeNewswire) +6.12%
Feb-20-25 09:50AM	Anbio Biotechnology Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-18-25 06:10PM	Anbio Biotechnology Announces Pricing of Initial Public Offering (GlobeNewswire)

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Anbio Biotechnology

Upgrade your FINVIZ experience